GTN Therapy on Biomarkers of Immune Escape in Men With Biochemical Recurrence of Prostate Cancer After Primary Therapy

NCT01704274 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

43

Enrollment

OTHER

Sponsor class

Conditions

Prostate Cancer

Interventions

OTHER: Low Dose GTN 0.0285 mg/hr
OTHER: High Dose GTN 0.057 mg/hr
OTHER: Placebo

Sponsor

Dr. D. Robert Siemens